Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-hodgkin's lymphoma

Radiotherapy and Oncology

Volumn 109, Issue 1, 2013, Pages 133-139

  Verhappen, Marieke H ^a   Poortmans, Philip M P ^a   Raaijmakers, Esther ^a   Raemaekers, John M M ^b  

^a Institute Verbeeten   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Involved field radiation therapy; Involved node radiation therapy; Malignant lymphoma; Non hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ACUTE TOXICITY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; INVOLVED FIELD RADIATION THERAPY; INVOLVED NODE RADIATION THERAPY; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION DOSE REDUCTION; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

CHEMOTHERAPY; INVOLVED FIELD RADIATION THERAPY; INVOLVED NODE RADIATION THERAPY; MALIGNANT LYMPHOMA; NON-HODGKIN'S LYMPHOMA;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HEART; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 84888069275     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.07.013     Document Type: Article

References (40)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
2. J. Phan, A. Mazloom, and L. Jeffrey Medeiros Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy J Clin Oncol 28 2010 4170 4176
3. T.P. Miller, S. Dahlberg, and J.R. Cassady Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma N Engl J Med 339 1998 21 26
4. T. Biswas, E. Culakova, and J.W. Friedberg Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma Radiother Oncol 103 2012 367 372
5. J. Yahalom Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains J Clin Oncol 28 2010 4105 4107
6. D.O. Persky, and T.P. Miller Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol 21 2009 401 406
7. A. Wirth The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era Leuk Lymphoma 48 2007 2121 2136
8. A. Engert, P. Schiller, and A. Josting Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group J Clin Oncol 21 2003 3601 3608
9. B. Klimm, H.T. Eich, and H. Haverkamp Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group Ann Oncol 18 2007 357 363
10. R. Zittoun, A. Audebert, and B. Hoerni Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease J Clin Oncol 3 1985 207 214
11. G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results J Clin Oncol 22 2004 2835 2841
12. B.A. Campbell, N. Voss, and R. Woods Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy Cancer 116 2010 3797 3806
13. B.A. Campbell, C. Hornby, and J. Cunninghame Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy Ann Oncol 23 2012 1259 1266
14. M.V. Maraldo, M.C. Aznar, I.R. Vogelius, P.M. Petersen, and L. Specht Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma Int J Radiat Oncol Biol Phys 85 2013 1057 1065
15. L. Cella, R. Liuzzi, and M. Conson Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma Radiother Oncol 101 2011 316 321
16. M.V. Maraldo, N.P. Brodin, and I.R. Vogelius Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma Int J Radiat Oncol Biol Phys 83 2012 1232 1237
17. L. Cella, M. Conson, and M.C. Pressello Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms Radiat Oncol 8 2013 22
18. L. Cella, R. Liuzzi, and M. Magliulo Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques Radiat Oncol 5 2010 33
19. M. Martelli, V. De Sanctis, G. Avvisati, and F. Mandelli Current guidelines for the management of aggressive non-Hodgkin's lymphoma Drugs 53 1997 957 972
20. L. Lowry, P. Smith, and W. Qian Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial Radiother Oncol 100 2011 86 92
21. T. Girinsky, R. van der Maazen, and L. Specht Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines Radiother Oncol 79 2006 270 277
22. S.H. Swerdlow, E. Campo, and N.L. Harris WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2008 IARC Press Lyon, France
23. P.P. Carbone, H.S. Kaplan, K. Musshoff, D.W. Smithers, and M. Tubiana Report of the committee on the staging of Hodgkin's disease. Report of the committee on Hodgkin's disease staging classification Cancer Res 31 1971 1860 1861
24. E.M. Noordijk, J. Thomas, and C. Ferme First results of the EORTC-GELA randomized trials: the H9-F trial (comparing 3 radiation dose levels) and the H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable stage Hodgkin's lymphoma (HL) J Clin Oncol 23 2005 6505 [Abstract]
25. C. Fermé, H. Eghbali, and J.H. Meerwaldt Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease N Engl J Med 357 2007 1916 1927
26. T. Girinsky, L. Specht, and M. Ghalibafian The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines Radiother Oncol 88 2008 202 210
27. B.D. Cheson, B. Pfistner, and M.E. Juweid International harmonization project on lymphoma. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 786
28. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Website: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm.
29. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
30. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
31. F. Reyes, E. Lepage, and G. Ganem ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma N Engl J Med 352 2005 1197 1205
32. P. Feugier, A. Van Hoof, and C. Sebban Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126
33. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242
34. L.H. Sehn, J. Donaldson, and M. Chhanabhai Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 2005 5027 5033
35. T.M. Habermann, E.A. Weller, and V.A. Morrison Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 2006 3121 3127
36. M. Pfreundschuh, A.D. Ho, and E. Cavallin-Stahl Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study Lancet Oncol 9 2008 435 444
37. N.S. Salemis, S. Gourgiotis, E. Tsiambas, G. Karagkiouzis, G. Nakos, and V. Karathanasis Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature J Gastrointest Cancer 40 2009 79 82
38. S.M. Hardy The sandwich sign Radiology 226 2003 651 652
39. N. Heutte, H.H. Flechtner, and N. Mounier Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial Lancet Oncol 10 2009 1160 1170
40. S.K. Smith, S. Zimmerman, C.S. Williams, and B.J. Zebrack Health status and quality of life among non-Hodgkin lymphoma survivors Cancer 115 2009 3312 3323